Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

First Posted Date
2023-02-22
Last Posted Date
2024-11-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
67
Registration Number
NCT05738291
Locations
🇳🇱

ICON-Groningen-62040, Groningen, Netherlands

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Phase 1
Completed
Conditions
Healthy
Liver Diseases
Interventions
Drug: BI 690517
First Posted Date
2023-02-16
Last Posted Date
2023-05-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT05731908
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Omega Research Orlando, LLC, Orlando, Florida, United States

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
Drug: BI 425809 (iclepertin)
First Posted Date
2023-02-16
Last Posted Date
2023-12-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT05731895
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Phase 1
Recruiting
Conditions
Psoriasis
Interventions
Drug: BI 765250
Drug: Placebo
First Posted Date
2023-02-15
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
80
Registration Number
NCT05728489
Locations
🇬🇪

ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia

🇧🇬

MBAL Sveta Sofia, Sofia, Bulgaria

🇲🇩

Clinical Republican Hospital "Timofei Mosneaga", Chisinau, Moldova, Republic of

and more 2 locations

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 425809
Drug: bosentan
First Posted Date
2023-02-13
Last Posted Date
2023-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT05723874
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Phase 1
Completed
Conditions
Renal Insufficiency
Healthy
Interventions
Drug: BI 1015550
First Posted Date
2023-02-08
Last Posted Date
2023-09-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT05718648
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Phase 1
Completed
Conditions
Renal Insufficiency
Interventions
Drug: BI 425809
First Posted Date
2023-02-08
Last Posted Date
2023-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT05718843
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

First Posted Date
2023-02-01
Last Posted Date
2024-11-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
180
Registration Number
NCT05708599
Locations
🇩🇪

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

First Posted Date
2023-01-31
Last Posted Date
2023-04-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT05707403
Locations
🇳🇱

ICON, Groningen, Netherlands

Safety of Nintedanib in Real World in China

First Posted Date
2023-01-09
Last Posted Date
2024-12-10
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT05676112
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy